Coherus BioSciences is on course to file a biologics license application in the US for partner Innovent Biologics’ Avastin (bevacizumab) biosimilar in the second half of 2021, management has revealed, after confirming that Coherus’ wholly-owned Humira (adalimumab) biosimilar application has now been filed with the US Food and Drug Administration.
“We project the BLA filing for the second half of 2021. The Phase III has been successfully completed by our...






